Merck & Co., Inc. (6MK.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 122.40 |
| Open | 121.60 |
| Bid | 121.40 x 0 |
| Ask | 122.00 x 0 |
| Day's range | 120.80 - 122.20 |
| 52-week range | 91.00 - 124.40 |
| Volume | |
| Avg. volume | 958 |
| Market cap | 308.523B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 145.00 |
| EPS (TTM) | 0.84 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 2.84 (2.33%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Insider MonkeyMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
© 2024 Yahoo. All rights reserved.